Effect of Single Dose of Ashwagandha Root Extract on Sexual Health in Women.
NCT ID: NCT07182253
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2025-03-31
2025-05-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is designed to explore whether Ashwagandha root extract (KSM-66), a natural herbal supplement known for its stress-reducing and vitality-enhancing properties, can help support and maintain sexual wellness in healthy adult women. Unlike treatments aimed at correcting dysfunction, this research focuses on enhancing natural sexual function-improving desire, mood, and satisfaction as part of overall health. Participants take either Ashwagandha or a placebo over several weeks, and their experiences are measured using validated tools like the Female Sexual Function Index (FSFI).
Understanding and supporting sexual wellness through natural means can improve not only intimacy and relationship satisfaction, but also self-esteem, mood, and general life satisfaction. By addressing sexual health proactively in healthy individuals, this study contributes to a more complete picture of women's health and well-being.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Arm 1: Interventional KSM-66 Ashwagandha® capsule (300 mg)
KSM-66 Ashwagandha root extract
KSM-66 Ashwagandha® capsule
Two off-white capsules, each containing 300 mg KSM-66 Ashwagandha root extract powder only.
Treatment Arm 2: Identical placebo capsule
Starch
Identical Placebo capsule
Two off-white capsules containing starch powder only
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KSM-66 Ashwagandha® capsule
Two off-white capsules, each containing 300 mg KSM-66 Ashwagandha root extract powder only.
Identical Placebo capsule
Two off-white capsules containing starch powder only
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
6\. Participant's partner is expected to be physically present at least 50% of each month.
7\. Participants who have used a medically acceptable method of contraception for at least 3 months before the baseline Visit (Visit 1) and continue to use that medically acceptable method of contraception during the trial.
8\. Participants who are reliable, honest, compliant, and agree to co-operate with all trial evaluations as well as to be able to perform them as per investigator's opinion.
9\. Participants or LAR can and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements.
10\. Participants having sufficient understanding to communicate effectively with the investigator and are willing to discuss their sexual functioning with the investigative staff.
11\. Participants who are willing to have 4 or more attempts of sexual intercourse each month.
Exclusion Criteria
3\. Participants having any clinically significant medical history, medical finding or an on- going medical or psychiatric condition exists which in the opinion of the Investigator could jeopardize the safety of the subject, impact validity of the study results or interfere with the completion of study according to the protocol.
4\. Individuals participating in any other studies, including macro/micro/any other forms of dietary supplements/multivitamins or disease-specific oral nutrition supplements (for improving the sexual function during the 3 months prior to study commencement).
5\. Participants having a history of hypersensitivity reactions (i.e., allergic or oversensitivity to usual doses).
6\. Participants with current alcohol or drug addiction or with a history of drug dependence or abuse within the past one year.
7\. Participants who indicate that their sexual partner has inadequately treated sexual problems that could interfere with the Subjects response to treatment.
8\. Participants who have entered the menopausal transition or menopause or have had a hysterectomy.
9\. Participants with findings of infection, inflammation, undue tenderness, or shrinkage (atrophy) of the female genital organs, at the Screening Visit.
10\. Participants who are breastfeeding or have breastfed within the last 6 months prior to the Baseline Visit.
11\. Participants who are pregnant or have been pregnant within the last 6 months prior to the Baseline Visit.
12\. Participants having primary hypoactive sexual desire. 13. Participants with a history of malignancy. 14. Participate itself are not planning to get pregnant for next six months 15. Participants who cannot cooperate to complete the subject records during the study.
18 Years
55 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SF Research Institute, Inc.
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Francisco Research Institute
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ixoreal-FSD-CT-1022
Identifier Type: -
Identifier Source: org_study_id